News | May 14, 2024
Lonza reports softer performance in Q1 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Investing in Malaysia's largest clinic operator to expand the healthcare business
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
2024 full-year revenue guidance raised by US$ 2 billion
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
The proposed facility is expected to be operational around January, 2027
The demand in Africa for COVID-19 vaccines has declined
Subscribe To Our Newsletter & Stay Updated
